

Eleftherios P Mamounas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6929700/publications.pdf>

Version: 2024-02-01

72
papers

25,942
citations

71061

41
h-index

95218

68
g-index

72
all docs

72
docs citations

72
times ranked

15472
citing authors

#	ARTICLE	IF	CITATIONS
1	Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 1673-1684.	13.9	4,956
2	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. <i>Lancet</i> , The, 2014, 384, 164-172.	6.3	3,224
3	Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2010, 11, 927-933.	5.1	1,477
4	Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18. <i>Journal of the National Cancer Institute Monographs</i> , 2001, 2001, 96-102.	0.9	1,100
5	The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27. <i>Journal of Clinical Oncology</i> , 2003, 21, 4165-4174.	0.8	1,018
6	Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. <i>Lancet</i> , The, 1999, 353, 1993-2000.	6.3	957
7	Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. <i>Lancet Oncology</i> , The, 2007, 8, 881-888.	5.1	915
8	Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. <i>Journal of Clinical Oncology</i> , 2006, 24, 2019-2027.	0.8	850
9	Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. <i>Journal of Clinical Oncology</i> , 2014, 32, 3744-3752.	0.8	771
10	Lumpectomy Compared with Lumpectomy and Radiation Therapy for the Treatment of Intraductal Breast Cancer. <i>New England Journal of Medicine</i> , 1993, 328, 1581-1586.	13.9	707
11	Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS. <i>Journal of the National Cancer Institute</i> , 2011, 103, 478-488.	3.0	660
12	Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31. <i>Journal of Clinical Oncology</i> , 2011, 29, 3366-3373.	0.8	646
13	Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28. <i>Journal of Clinical Oncology</i> , 2005, 23, 3686-3696.	0.8	585
14	Tamoxifen, Radiation Therapy, or Both for Prevention of Ipsilateral Breast Tumor Recurrence After Lumpectomy in Women With Invasive Breast Cancers of One Centimeter or Less. <i>Journal of Clinical Oncology</i> , 2002, 20, 4141-4149.	0.8	580
15	Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor-Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20. <i>Journal of Clinical Oncology</i> , 2010, 28, 1677-1683.	0.8	538
16	Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer: Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27. <i>Journal of Clinical Oncology</i> , 2005, 23, 2694-2702.	0.8	492
17	Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. <i>Journal of Clinical Oncology</i> , 2012, 30, 3960-3966.	0.8	473
18	Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the National Surgical Adjuvant Breast and Bowel Project experience. <i>Seminars in Oncology</i> , 2001, 28, 400-418.	0.8	463

#	ARTICLE	IF	CITATIONS
19	Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Five National Surgical Adjuvant Breast and Bowel Project Node-Positive Adjuvant Breast Cancer Trials. <i>Journal of Clinical Oncology</i> , 2006, 24, 2028-2037.	0.8	418
20	Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. <i>European Journal of Cancer</i> , 2012, 48, 3342-3354.	1.3	410
21	Effect of Occult Metastases on Survival in Node-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2011, 364, 412-421.	13.9	399
22	Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2466-2473.	0.8	397
23	Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. <i>Journal of Surgical Oncology</i> , 2010, 102, 111-118.	0.8	387
24	Patterns of Locoregional Failure in Patients With Operable Breast Cancer Treated by Mastectomy and Adjuvant Chemotherapy With or Without Tamoxifen and Without Radiotherapy: Results From Five National Surgical Adjuvant Breast and Bowel Project Randomized Clinical Trials. <i>Journal of Clinical Oncology</i> , 2004, 22, 4247-4254.	0.8	348
25	Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the national surgical adjuvant breast and bowel project experience. <i>Seminars in Oncology</i> , 2001, 28, 400-418.	0.8	339
26	Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP B-31). <i>Journal of Clinical Oncology</i> , 2010, 28, 332-340.	9.1	332
27	Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. <i>Lancet</i> , 2019, 394, 2155-2164.	6.3	319
28	Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 1965-1971.	0.8	317
29	Meta-Analysis of Magnetic Resonance Imaging in Detecting Residual Breast Cancer After Neoadjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2013, 105, 321-333.	3.0	298
30	Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. <i>Lancet Oncology</i> , 2014, 15, 156-163.	5.1	171
31	Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. <i>Lancet</i> , 2016, 387, 849-856.	6.3	148
32	Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. <i>Lancet Oncology</i> , 2015, 16, 1037-1048.	5.1	138
33	21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw259.	3.0	116
34	Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG B-15). <i>Lancet Oncology</i> , 2019, 20, 88-99.	5.1	108
35	Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis. <i>BMC Cancer</i> , 2015, 15, 662.	1.1	106
36	Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1073-1079.	0.8	102

#	ARTICLE	IF	CITATIONS
37	Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (<i>ESR1</i>) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14. <i>Journal of Clinical Oncology</i> , 2016, 34, 2350-2358.	0.8	71
38	Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. <i>Lancet, The</i> , 2016, 387, 857-865.	6.3	67
39	Impact of Neoadjuvant Chemotherapy on Locoregional Surgical Treatment of Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 1425-1433.	0.7	58
40	Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2. <i>Journal of Clinical Oncology</i> , 2017, 35, 3942-3948.	0.8	55
41	Current approach of the axilla in patients with early-stage breast cancer. <i>Lancet, The</i> , 2017, , .	6.3	53
42	NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypNO after neoadjuvant chemotherapy (NC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS600-TPS600.	0.8	38
43	The importance of systemic therapy in minimizing local recurrence after breast-conserving surgery: The NSABP experience. <i>Journal of Surgical Oncology</i> , 2014, 110, 45-50.	0.8	36
44	21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 69-77.	1.1	36
45	Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial. <i>Annals of Surgical Oncology</i> , 2017, 24, 398-406.	0.7	29
46	Pathologic findings from the national surgical adjuvant breast project (NSABP) protocol B-17: Intraductal carcinoma (ductal carcinoma in situ). <i>Cancer</i> , 1995, 76, 2385-2387.	2.0	26
47	Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv304.	3.0	19
48	Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41.. <i>Journal of Clinical Oncology</i> , 2016, 34, 501-501.	0.8	19
49	Timing of Determining Axillary Lymph Node Status When Neoadjuvant Chemotherapy is Used. <i>Current Oncology Reports</i> , 2014, 16, 364.	1.8	18
50	Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2367-2374.	0.8	16
51	Response-blunting the counterpoint. <i>Cancer</i> , 1995, 75, 1223-1227.	2.0	14
52	Ipsilateral Breast Tumor Recurrence After Lumpectomy: Is It Time to Take the Bull by the Horns?. <i>Journal of Clinical Oncology</i> , 2001, 19, 3798-3800.	0.8	12
53	Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090,) Tj ETQq1 1 0.784314 rgBT /Over anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1000-1000.	0.8	12
54	Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 508-508.	0.8	11

#	ARTICLE	IF	CITATIONS
55	NRG Oncology BRO05: Phase II trial assessing accuracy of tumor bed biopsies (Bx) in predicting pathologic response in patients (Pts) with clinical/radiological complete response (CR) after neoadjuvant chemotherapy (NCT) in order to explore the feasibility of breast-conserving treatment (BCT) without surgery.. Journal of Clinical Oncology, 2018, 36, TPS604-TPS604.	0.8	10
56	Optimal Management of the Axilla. Advances in Surgery, 2016, 50, 29-40.	0.6	9
57	Optimizing Surgical Management of the Axilla After Neoadjuvant Chemotherapy: An Evolving Story. Annals of Surgical Oncology, 2018, 25, 2124-2126.	0.7	9
58	NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence free interval (IBCRFI) in patients (pts) with positive axillary (PAx) nodes who are ypNO after neoadjuvant chemotherapy (NC).. Journal of Clinical Oncology, 2017, 35, TPS589-TPS589.	0.8	9
59	Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group. FB-5. Clinical Breast Cancer, 2017, 17, 48-54.e3.	1.1	8
60	Omitting Surgery in Complete Responders After Neoadjuvant Chemotherapy: The Quest Continues. Annals of Surgical Oncology, 2018, 25, 3119-3122.	0.7	7
61	Neoadjuvant Systemic Therapy for Breast Cancer: Factors Influencing Surgeons' Referrals. Annals of Surgical Oncology, 2016, 23, 3510-3517.	0.7	6
62	NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.. Journal of Clinical Oncology, 2018, 36, TPS603-TPS603.	0.8	6
63	Primary results of NRG Oncology / NSABP B-43: Phase III trial comparing concurrent trastuzumab (T) and radiation therapy (RT) with RT alone for women with HER2-positive ductal carcinoma in situ (DCIS) after lumpectomy.. Journal of Clinical Oncology, 2020, 38, 508-508.	0.8	5
64	Neoadjuvant Therapy for Early-Stage Breast Cancer: A Model for Individualizing Outcomes and Tailoring Locoregional and Systemic Therapy. Oncology, 2015, 29, 839-40, 846.	0.4	5
65	Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trial.. Journal of Clinical Oncology, 2018, 36, 580-580.	0.8	4
66	NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with positive axillary (PAx) nodes who are ypNO after neoadjuvant chemotherapy (NC).. Journal of Clinical Oncology, 2018, 36, TPS601-TPS601.	0.8	4
67	NRG Oncology/NSABP B-31: Stromal tumor infiltrating lymphocytes (sTILs) and outcomes in early-stage HER2-positive breast cancer (BC).. Journal of Clinical Oncology, 2018, 36, 12010-12010.	0.8	2
68	New issues in breast cancer surgical management. , 2006, , 115-161.		2
69	The Impact of Neoadjuvant Chemotherapy on Local-Regional Treatment of Breast Cancer. Current Breast Cancer Reports, 2013, 5, 106-117.	0.5	1
70	Lumpectomy margins: Everything old is new again?. Surgical Oncology, 2015, 24, 5-8.	0.8	0
71	Abstract 532: Association of pCR and the 8-gene signature: NRG Oncology/NSABP B-41. , 2021, , .		0
72	NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence free interval (IBCRFI) in patients (pts) with positive axillary (PAx) nodes who are ypNO after neoadjuvant chemotherapy (NC).. Journal of Clinical Oncology, 2016, 34, TPS1097-TPS1097.	0.8	0